Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 9, 2016, Pages 944-951

  Patti, F ^a   Messina, S ^a   Solaro, C ^b   Amato, M P ^c   Bergamaschi, R ^d   Bonavita, S ^e   Bruno Bossio, R ^f   Brescia Morra, V ^e   Costantino, G F ^g   Cavalla, P ^h   Centonze, D ^i,j   Comi, G ^k   Cottone, S ^l   Danni, M ^m   Francia, A ⁿ   Gajofatto, A ^o   Gasperini, C ^p   Ghezzi, A ^q   Iudice, A ^r   Lus, G ^s   Maniscalco, G T ^t   Marrosu, M G ^u   Matta, M ^v   Mirabella, M ^w   Montanari, E ^x   Pozzilli, C ^y   Rovaris, M ^z   Sessa, E ^aa   Spitaleri, D ^ab   Trojano, M ^ac   Valentino, P ^ad   Zappia, M ^a   more..

^a UNIVERSITY OF CATANIA   (Italy)

^b Neurology Unit   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Neurology Operating Unit Serraspiga   (Italy)

^g Hospital of Foggia   (Italy)

^h MOLINETTE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF ROME TOR VERGATA   (Italy)

^j IRCCS NEUROMED   (Italy)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^m Ancona Hospital   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o UNIVERSITY OF VERONA   (Italy)

^p SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^q Sant'Antonio Abate Hospital   (Italy)

^r UNIVERSITY HOSPITAL OF PISA   (Italy)

^s SECOND UNIVERSITY OF NAPLES   (Italy)

^t CARDARELLI HOSPITAL   (Italy)

^u UNIVERSITY OF CAGLIARI   (Italy)

^v SAN LUIGI GONZAGA HOSPITAL   (Italy)

^w CATHOLIC UNIVERSITY   (Italy)

^x Vaio Hospital   (Italy)

^y SAPIENZA UNIVERSITY OF ROME   (Italy)

^z IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^aa IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^ab S G MOSCATI HOSPITAL   (Italy)

^ac UNIVERSITY OF BARI   (Italy)

^ad UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NABIXIMOLS;

ADULT; ALLERGIC REACTION; ARTICLE; COGNITIVE DEFECT; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOUTH DISCOMFORT; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE ASSESSMENT; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SPASTICITY; TREATMENT DURATION; CLINICAL TRIAL; MULTICENTER STUDY;

EID: 84969138568     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-312591     Document Type: Article

References (21)

1. Arroyo R, Vila C, Clissold S. Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the '5E' study. Expert Rev Pharmacoecon Outcomes Res 2011;11:205-13.
2. Rizzo MA, Hadjimichael OC, Preiningerova J, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10:589-95.
3. Pozzilli C. Overview of MS spasticity. Eur Neurol 2014;71(Suppl 1):1-3.
4. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:iii, ix-x, 1-111.
5. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003;(4):CD001332.
6. Collin C, Davies P, Mutiboko IK, et al, Sativex spasticity in MSSG. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6.
7. Meuth SG, Vila C, Dechant KL. Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis. Expert Rev Neurother 2015;15:909-18.
8. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006;42:495-503.
9. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41.
10. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45.
11. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9.
12. Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31.
13. Fernández O. Advances in the management of MS spasticity: recent observational studies. Eur Neurol 2014;72(Suppl 1):12-14.
14. Eltayb A, Etges T, Wright S. An observational post-approval registry study of patients prescribed Sativex ®. Results from clinical practice. [Poster 1041]. Mult Scler 2013;19(Suppl 1):74.
15. Koehler J, Feneberg W, Meier M, et al. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 2014;124:652-6.
16. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71:271-9.
17. Celia Oreja-Guevara BC, Manuel Ordás C, Vila C, et al. Observational safety study of THC:CBD oromucosal spray (Sativex) in multiple sclerosis patients with spasticity. Clin Exp Pharmacol 2015;5:184.
18. Farrar JT, Troxel AB, Stott C, et al. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther 2008;30:974-85.
19. Flachenecker P, Henze T, Zettl UK. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 2014;72:95-102.
20. Ferrè L, Nuara A, Pavan G, et al. Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci 2016;37:235-42.
21. Leocani L, Nuara A, Houdayer E, et al. Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol 2015;262: 2520-7.